Serum magnesium and C-reactive protein levels

Archives of Disease in Childhood

Volumn 93, Issue 8, 2008, Pages 676-680

  Rodriguez Moran M ^a   Guerrero Romero, Fernando ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; MAGNESIUM; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMAGNESEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEXICO; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY MASS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; METABOLISM; OBESITY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHILD; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; MEXICO; OBESITY; OVERWEIGHT; STATISTICS AS TOPIC; TRIGLYCERIDES;

EID: 49049121887     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.109371     Document Type: Article

References (43)

1. Mc Gill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. Arterioscler Thromb Vasc Biol 2000;20:1998-2004.
2. Webber LS, Harsha DW, Phillips GT, et al. Cardiovascular risk factors in Hispanic, white, and black children: The Brooks County and Bogalusa Heart Studies. Am J Epidem 1991;133:704-14.
3. Tracy RE, Newman WP 3rd, Wattigney WA, et al. Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. Am J Med Sci 1995;310(Suppl 1):S37-S41.
4. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6.
5. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocytes recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.
6. Ross R. Atherosclerosis: an inflammatory disease. N Eng J Med 1999;340:115-26.
7. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Eng J Med 2004;350:1387-97.
8. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
9. rd edn. Oxford: Oxford University Press, 1995:1527-1533.
10. Festa A, D'Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:1131-7.
11. Lopez Martinez J, Sanchez Castilla M, Garcia de Lorenzo y Mateos A, et al. Magnesium: metabolism and requirements. Nutr Hosp 1997:4-14.
12. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens 1997;10:346-55.
13. Guerrero-Romero F, Rodríguez-Morán M. Complementary therapies for diabetes: The case for chromium, magnesium, and antioxidants. Arch Med Res 2005;36:250-7.
14. Guerrero-Romero F, Rodríguez-Morán M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002;39:209-13.
15. Kao WHL, Folsom AR, Nieto FJ, et al. Serum and dietary magnesium and the risk for type 2 diabetes mellitus. Arch Intern Med 1999;159:2151-9.
16. Kisters K, Spieker C, Tepel M, et al. New data about the effect of oral physiological magnesium supplementation on several cardiovascular risk factors (lipids and blood pressure). Magnes Res 1993;6:355-60.
17. Guerrero-Romero F, Rodríguez-Morán M. Hypomagnesemia is linked to low serum HDL-cholesterol irrespective of serum glucose values. J Diabetes Complicat 2000;14:272-6.
18. Guerrero-Romero F, Rodríguez-Moran M. Hypomagnesemia, oxidative stress, inflammation, and metabolic síndrome. Diabet Metab Res Rev 2006;22:471-6.
19. Kramer JH, Mak IT, Phillips TM, et al. Dietary magnesium intake influences circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to post-ischemic stress. Exp Biol Med 2003;228:665-73.
20. Dong A, Caughey WS, Du Clos TW. Effects of calcium, magnesium, and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. J Biol Chem 1994;269:6424-30.
21. Cook DG, Mendall MA, Whincup PH, et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139-50.
22. Ford ES, Galuska DA, Gillespie C, et al. C-reactive protein and body mass index in children: findings from Third National Health and Nutrition Examination Survey, 1988-1994. J Pediatr 2001;138:486- 92.
23. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height, height velocity and weight velocity: British children, 1965. I. Arch Dis Child 1966;41:454-71.
24. Maffeis C, Pietrobelli A, Grezzani A, et al. Waist circumference and cardiovascular risk factors in prepubertal children. Obes Res 2001;9:179-1787.
25. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
26. Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J 2000;320:1240-3.
27. Guerrero-Romero F, Rodríguez-Morán M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab 2003;29:65-71.
28. Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 2002;26:469-74.
29. King DE, Mainous AG 3rd, Geesey ME, et al. Dietary magnesium and C-reactive protein levels. J Am Coll Nutr 2005;24:166-71.
30. Song Y, Ridker PM, Manson JE, et al. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005;28:1438-44.
31. Ford ES, Giles WH, Myers GL, et al. C-reactive protein concentration distribution among US children and young adults: Findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem 2003;49:1353-7.
32. Lambert M, Delvin EE, Pradis G, et al. C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin Chem 2004;10:1762-8.
33. Visser M, Bouter LM, McQuillan GM, et al. Low-grade systemic inflammation in overweight children. Pediatrics 2001;107:E13.
34. Ford ES. C-reactive protein concentration and cardiovascular disease risk factors in children. Findings from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2003;108:1053- 8.
35. Ahsan SK, al-Swoyan S, Hanif M, et al. Hypomagnesemia and clinical implications in children and neonates. Indian J Med Sci 1998;52:541-7.
36. Moran A, Steffen LM, Jacobs DR Jr, et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 2005;28:1763-8.
37. Ford EA, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005;28:878-81.
38. Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care 2005;28:1175-81.
39. Weglicki WB, Mak IT, Stafford RE, et al. Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Mol Cell Biochem 1994;130:103-9.
40. Weglicki WB, Mak IT, Phillips TM. Blockade of cardiac inflammation in Mg2+ deficiency by substance P receptor inhibition. Cir Res 1994;74:1009-13.
41. Malpuech-Brugère C, Nowacki W, Daveau M, et al. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta 2000;1501:91-8.
42. Rosolova H, Mayer O Jr, Reaven GM. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. Metabolism 2000;49:418-20.
43. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: heath implications for the 21st century. Am J Clin Nutr 2005;81:341-54.